-
Product Sales up a robust 14% over prior year, and a signifi
Source: Buzz FX / 09 May 2024 16:26:29 America/New_York
Product Sales up a robust 14% over prior year, and a significant 22% sequentially
We believe the STAR-T data presented at AATS support a favorable benefit-to-risk profile of DrugSorb-ATR in coronary artery bypass graft (CABG) patients On tr
Read more...